<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Molnupiravir (United States: Authorized for use): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Molnupiravir (United States: Authorized for use): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Molnupiravir (United States: Authorized for use): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="134698" href="/d/html/134698.html" rel="external">see "Molnupiravir (United States: Authorized for use): Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="134699" href="/d/html/134699.html" rel="external">see "Molnupiravir (United States: Authorized for use): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56833140"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lagevrio</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56466784"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiviral Agent</li></ul></div>
<div class="block doa drugH1Div" id="F56472472"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd039419-3dc9-408e-9987-a336010fc3a2">COVID-19, mild to moderate; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, mild to moderate; treatment (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients at high risk of progression to severe COVID-19, including hospitalization or death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021','lexi-content-ref-NIH.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021','lexi-content-ref-NIH.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>800 mg every 12 hours for 5 days; initiate as soon as possible after COVID-19 diagnosis, and within 5 days of symptom onset. After initiating treatment with molnupiravir, if hospitalization is required, completion of 5-day course is at the health care provider's discretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36566761','lexi-content-ref-FDA.2021','lexi-content-ref-34914868','lexi-content-ref-NIH.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36566761','lexi-content-ref-FDA.2021','lexi-content-ref-34914868','lexi-content-ref-NIH.2'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Missed dose:</i></b>If a dose is missed within 10 hours of usual administration time, administer the missed dose as soon as possible, and resume normal dosing schedule. If a dose is missed by more than 10 hours, do not administer the missed dose, and resume dosing at the next scheduled administration time. Do not double the dose to make up for a missed dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p></div>
<div class="block dora drugH1Div" id="F56472474"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function </b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>). <b>Note:</b> Molnupiravir has not been formally evaluated in this population, but kidney impairment is unlikely to substantially impact pharmacokinetics as only 3% is eliminated in the urine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>). Several case series report the safety and tolerability of molnupiravir in patients with eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>; nausea may be more common in patients with chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36948600','lexi-content-ref-36362691','lexi-content-ref-37037486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36948600','lexi-content-ref-36362691','lexi-content-ref-37037486'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b>
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzability (unknown; has not been studied):</p>
<p style="text-indent:-2em;margin-left:4em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); when scheduled doses fall on a hemodialysis day, administration after hemodialysis may be preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37037486','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37037486','lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Molnupiravir has not been formally evaluated in this population, but kidney impairment is unlikely to substantially impact pharmacokinetics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>). Several case series support the safety and tolerability of molnupiravir in patients receiving hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36948600','lexi-content-ref-36362691','lexi-content-ref-37037486','lexi-content-ref-36298779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36948600','lexi-content-ref-36362691','lexi-content-ref-37037486','lexi-content-ref-36298779'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b> Note:</b> Molnupiravir has not been formally evaluated in this population, but kidney impairment is unlikely to substantially impact pharmacokinetics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Since there are no data describing the pharmacokinetics of molnupiravir in critical illness or in patients receiving CRRT the use of an alternative agent may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>No dosage adjustment likely to be necessary; when scheduled dose falls on a PIRRT day, administer after PIRRT may be preferred when feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Since there are no data describing the pharmacokinetics of molnupiravir in critical illness or in patients receiving PIRRT the use of an alternative agent may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F56472475"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F56472473"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F56483387"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="134698" href="/d/html/134698.html" rel="external">see "Molnupiravir (United States: Authorized for use): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Do not use in patients &lt;18 years of age due to the potential for bone and cartilage toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd039419-3dc9-408e-9987-a336010fc3a2">COVID-19, mild to moderate; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, mild to moderate; treatment (outpatients with high risk of progression to severe illness) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Oral: 800 mg every 12 hours for 5 days; initiate as soon as possible after COVID-19 diagnosis, and within 5 days of symptom onset. After initiating treatment with molnupiravir, if hospitalization is required, completion of 5-day course is at the health care provider's discretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021','lexi-content-ref-34914868']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021','lexi-content-ref-34914868'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F56483388"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Adolescents ≥18 years: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F56483389"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Adolescents ≥18 years: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F58656583"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions, including <b>anaphylaxis</b> and <b>angioedema</b>, have been reported. Delayed hypersensitivity reactions, including <b>skin rash</b>, <b>acne vulgaris</b>, <b>allergic dermatitis</b>, and <b>exfoliation of the skin</b>, have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36928787','lexi-content-ref-33649113','lexi-content-ref-35643856','lexi-content-ref-36614834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36928787','lexi-content-ref-33649113','lexi-content-ref-35643856','lexi-content-ref-36614834'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic. Immediate hypersensitivity reactions (eg, anaphylaxis) can be non–IgE-mediated or IgE-mediated. Delayed hypersensitivity reactions, including rash, are commonly T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). Delayed hypersensitivity reactions: Nonspecific rash: Intermediate; occur 6 to 10 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NICE.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56477884"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">Adverse reactions and incidences are derived from the FDA-issued emergency use authorization (EUA). Adverse reactions reported in adults. Refer to EUA for information regarding reporting adverse reactions (FDA 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Post-authorization:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (Pupo Correia 2022), allergic dermatitis (Pupo Correia 2022), erythema of skin, exfoliation of skin (Pupo Correia 2022), pruritus (Pupo Correia 2022), skin rash (Pupo Correia 2022), urticaria (Kimata 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (Kimata 2023), vomiting (Kimata 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (Kimata 2023), headache (Kimata 2023)</p></div>
<div class="block coi drugH1Div" id="F56466788"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the FDA emergency use authorization (EUA) fact sheet for health care providers.</p></div>
<div class="block war drugH1Div" id="F56472459"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone and cartilage effects: Bone and cartilage toxicity was observed in animals after repeat dosing; molnupiravir is not authorized for use in patients &lt;18 years of age because it may affect bone and cartilage growth (FDA 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other</b>
<b> warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Viral rebound: Viral rebound and recurrence of COVID-19 symptoms have been reported in some patients after completing treatment. The frequency, mechanism, and clinical implications of these events are unclear. Viral rebound and recurrence of COVID-19 symptoms can occur in the absence of treatment. Concern for viral rebound and/or recurrence of symptoms should not be a reason to avoid antiviral therapy (NIH 2023).</p></div>
<div class="block prod-avail drugH1Div" id="F56466789"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Molnupiravir approved for emergency use authorization by the FDA December 2021.</p></div>
<div class="block foc drugH1Div" id="F56674078"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lagevrio: 200 mg</p></div>
<div class="block geq drugH1Div" id="F56674077"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56695233"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Lagevrio Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F56472457"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:-2em;margin-left:2em;">Molnupiravir is not commercially available; it is available as part of ongoing clinical trials and under an emergency use authorization (EUA) from the FDA. Molnupiravir is available from the distributor, AmerisourceBergen.</p>
<p style="text-indent:-2em;margin-left:2em;">As part of the EUA, information consistent with fact sheets pertaining to emergency use of molnupiravir are required to be available for health care providers and patients/caregivers, and certain mandatory requirements for molnupiravir administration under the EUA must be met as outlined in the FDA EUA letter; the fact sheets may be accessed at https://www.molnupiravir.com. Additionally, health care providers must track and report all medication errors and serious adverse events potentially associated with molnupiravir use by either submitting a MedWatch form (<a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedwatch%2Freport.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPNcm5lNJ%2BSfidIV4m5OTN5Ih2EApxCjHbBkH0Y1jxFob&amp;TOPIC_ID=134694" target="_blank">https://www.fda.gov/medwatch/report.htm</a>), FDA Form 3500 (health professional; available at: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-forms-fda-safety-reporting%2Finstructions-completing-form-fda-3500&amp;token=JawecUzmcWoycZF2aiaddFxIves895jp9lZnR66bz83WN1VdAJfKm2uDiFTzGKZvRVWk827gL5rCvQqtlXj0ONBs3Pf7poW87Tbg8WYt%2FfzGssLuYYtX1iG0rPt5gSzB&amp;TOPIC_ID=134694" target="_blank">https://www.fda.gov/safety/medwatch-forms-fda-safety-reporting/instructions-completing-form-fda-3500</a>) by mail (MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787) or fax (1-800-FDA-0178), or by calling 1-800-FDA-1088 to request a reporting form; a copy of all MedWatch forms should also be provided to Merck &amp; Co., Inc. (phone: 1-800-672-6372; fax: 1-215-616-5677; e-mail: <a class="__cf_email__" data-cfemail="b5d1c5dad69bc0c6d4f5d8c6d19bd6dad8" href="/cdn-cgi/l/email-protection">[email protected]</a>).</p></div>
<div class="block adm drugH1Div" id="F56472476"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with or without food. Swallow capsules whole; do not open, break, or crush (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nasogastric or orogastric feeding tube (NG or OG tube): </i>For patients unable to swallow capsules whole, capsule contents may be dispersed in water to be administered via nasogastric (NG) or orogastric (OG) tube. Open capsules and transfer contents to a container with a lid; add 40 mL of water to the container and shake thoroughly (3 minutes). Flush NG/OG tube with 5 mL of water prior to administration; draw up entire contents in container using a catheter-tip syringe and administer immediately through the NG/OG tube (≥12F). If contents remain in container, add 10 mL of water to the container, mix, and draw up into the same syringe administering via the NG/OG tube; repeat as needed until container and syringe are empty. Flush NG/OG tube twice with 5 mL of water (10 mL total) after administering the mixture. <b>Note:</b> Capsule contents may not dissolve completely and visible undissolved particulates are acceptable; do not store mixture for future use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F56483391"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with or without food. Swallow capsules whole; do not open, break, or crush (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Nasogastric (NG) or orogastric (OG) tube (12 French or larger): Empty 4 capsules (800 mg) into a clean container with a lid. Add 40 mL water, close the lid, and shake for 3 minutes; capsule contents may not completely dissolve; undissolved particles are acceptable to administer. Flush NG or OG tube with 5 mL water, then administer prepared mixture immediately using a catheter tip syringe. If any capsule contents remain in container, add 10 mL of water, mix, and administer through the NG or OG tube with the same syringe; repeat as needed until no capsule contents remain in syringe or container. After administering the full dose, flush the NG or OG tube with 5 mL of water twice (10 mL total).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If a dose is missed within 10 hours of usual administration time, administer the missed dose as soon as possible, and resume normal dosing schedule. If a dose is missed by &gt;10 hours, do not administer the missed dose, and resume dosing at the next scheduled administration time. Do not double the dose to make up for a missed dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F56466786"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">See "Use: Off Label."</p></div>
<div class="block off-label drugH1Div" id="F56466787"><span class="drugH1">Use: Off-Label: Adult</span><p>COVID-19, treatment, mild to moderate (alternative agent)</p></div>
<div class="block cyt drugH1Div" id="F56425479"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56425476"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56477928"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate and verify pregnancy status prior to use in patients who may become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Pregnancy testing is recommended for patients who do not have regular menstrual cycles, who are unsure of the first day of their last cycle, or who do not use contraception correctly and consistently. Pregnancy status does not need confirmed in patients using an intrauterine system or contraceptive implant, patients who have undergone permanent sterilization, or when pregnancy is otherwise not possible.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who may become pregnant should use reliable contraception correctly and consistently during therapy and for 4 days after the last dose of molnupiravir. Sexually active males with partners who may become pregnant should also use effective contraception during therapy and for at least 3 months after the last molnupiravir dose.</p></div>
<div class="block pri drugH1Div" id="F56477929"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to molnupiravir may cause fetal harm. Molnupiravir is currently available under FDA emergency use authorization (EUA) for the treatment of COVID-19; pregnant patients were not eligible for inclusion in a phase 3 study (Jayk Bernal 2021).</p>
<p style="text-indent:0em;margin-top:2em;">The risk of severe illness from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients. Pregnant and recently pregnant patients with moderate or severe infection are at increased risk of complications such as hypertensive disorders of pregnancy, postpartum hemorrhage, or other infections compared to pregnant patients without COVID-19. Symptomatic pregnant patients may require ICU admission, mechanical ventilation, or ventilatory support (ECMO) compared to symptomatic nonpregnant patients. Other adverse pregnancy outcomes include preterm birth and stillbirth. The risk of coagulopathy, cesarean delivery, and maternal death may be increased; neonates have an increased risk for NICU admission. Maternal age and comorbidities such as diabetes, hypertension, lung disease, and obesity may also increase the risk of severe illness in pregnant and recently pregnant patients (ACOG 2022; NIH 2022).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the treatment of COVID-19 infection during pregnancy is the same as in nonpregnant patients. However, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process (NIH 2022). Use of molnupiravir in pregnancy is not recommended unless no other options are available, and therapy is clearly indicated. In pregnant patients at high risk of progressing to severe disease, use may be considered after the period of embryogenesis (eg, &gt;10 weeks' gestation) when preferred treatments are not available (NIH 2022). If the decision is made to use molnupiravir in a pregnant patient, the prescriber must document that the known and potential risks, as outlined in the Fact Sheet for Patients and Caregivers, have been communicated to the patient. Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to molnupiravir is ongoing. Health care providers must document that the pregnant patient was made aware of the molnupiravir pregnancy surveillance program. Health care providers must enroll patients who agree to participate (https://covid-pr.pregistry.com or 1-800-616-3791, or by contacting the manufacturer at 1-877-888-4231). Patients may also enroll themselves.</p></div>
<div class="block brc drugH1Div" id="F56477930"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if molnupiravir is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 4 days after the last molnupiravir dose; patients may express and discard breast milk during this time.</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to COVID-19 and breastfeeding is available from the World Health Organization (https://www.who.int/news/item/28-04-2020-new-faqs-address-healthcare-workers-questions-on-breastfeeding-and-covid-19).</p></div>
<div class="block mop drugH1Div" id="F56472478"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Pregnancy test prior to initiation, as clinically indicated (FDA 2023).</p></div>
<div class="block pha drugH1Div" id="F56472463"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Molnupiravir is metabolized to the cytidine nucleoside analog, NHC, which is further phosphorylated to the active ribonucleoside triphosphate (NHC-TP). NHC-TP is incorporated into SARS-CoV-2 RNA by viral RNA polymerase, resulting in errors in viral genome and subsequently inhibition of replication (FDA 2023).</p></div>
<div class="block phk drugH1Div" id="F56472464"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: NHC: 142 L (FDA 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: NHC: Does not appear to be protein bound (FDA 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Molnupiravir is metabolized to NHC; NHC undergoes phosphorylation to pharmacologically active ribonucleoside triphosphate.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: NHC: 3.3 hours (FDA 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: NHC: 1.5 hours (FDA 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: NHC: Urine (3%) (FDA 2023).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522419"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Emorivir | Molenzavir | Molvir | Monuvir</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Covapravir</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Movfor</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cipmolnu | Lizuvira | Molcovir | Molflu | Molnatris | Molnulup | Molnumize | Molnunat | Molnutor | Molulife | Molulow | Molunamax | Molviton | Molxvir | Movfor</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Molnovir | Monuvir</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Movfor</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Molnarz</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Esperavir</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Covinavir</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Rinovir</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lagevrio | Molcovir | Molflu | Molnaflu</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed October 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36566761">
<a name="36566761"></a>Butler CC, Hobbs FDR, Gbinigie OA, et al; PANORAMIC Trial Collaborative Group. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. <i>Lancet</i>. 2023;401(10373):281-293. doi:10.1016/S0140-6736(22)02597-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/36566761/pubmed" id="36566761" target="_blank">36566761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36948600">
<a name="36948600"></a>Cho WJ, Harden D, Moreno D, et al. Oral antiviral therapies for COVID-19 in patients with advanced chronic kidney disease or kidney failure. <i>Nephrol Dial Transplant</i>. 2023;38(8):1912-1914. doi:10.1093/ndt/gfad058<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/36948600/pubmed" id="36948600" target="_blank">36948600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36362691">
<a name="36362691"></a>Czarnecka K, Czarnecka P, Tronina O, Durlik M. Molnupiravir outpatient treatment for adults with COVID-19 in a real-world setting-a single center experience. <i>J Clin Med</i>. 2022;11(21):6464. doi:10.3390/jcm11216464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/36362691/pubmed" id="36362691" target="_blank">36362691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37037486">
<a name="37037486"></a>Dufour I, Devresse A, Scohy A, et al. Safety and efficiency of molnupiravir for COVID-19 patients with advanced chronic kidney disease. <i>Kidney Res Clin Pract</i>. 2023;42(2):275-278. doi:10.23876/j.krcp.22.194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/37037486/pubmed" id="37037486" target="_blank">37037486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34914868">
<a name="34914868"></a>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al; MOVe-OUT Study Group. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. <i>N Engl J Med</i>. Published online December 16, 2021. doi:10.1056/NEJMoa2116044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/34914868/pubmed" id="34914868" target="_blank">34914868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36928787">
<a name="36928787"></a>Kimata M, Watanabe A, Yanagida Y, Kinoshita D, Maekawa S. Safety and effectiveness of molnupiravir (LAGEVRIO<sup>®</sup>) capsules in Japanese patients with COVID-19: Interim report of post-marketing surveillance in Japan. <i>Infect Dis Ther</i>. 2023;12(4):1119-1136. doi:10.1007/s40121-023-00782-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/36928787/pubmed" id="36928787" target="_blank">36928787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lagevrio.1">
<a name="Lagevrio.1"></a>Lagevrio (molnupiravir) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lagevrio.1">
<a name="Lagevrio.1"></a>Lagevrio (molnupiravir) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated October 19, 2022. Accessed October 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2">
<a name="NIH.2"></a>National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated April 20, 2023. Accessed May 15, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. https://www.nice.org.uk/guidance/cg183. Published September 3, 2014. Accessed September 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33649113">
<a name="33649113"></a>Painter WP, Holman W, Bush JA, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. <i>Antimicrob Agents Chemother</i>. 2021;65(5):e02428-20. doi:10.1128/AAC.02428-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/33649113/pubmed" id="33649113" target="_blank">33649113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36298779">
<a name="36298779"></a>Poznański P, Augustyniak-Bartosik H, Magiera-Żak A, et al. Molnupiravir when used alone seems to be safe and effective as outpatient COVID-19 therapy for hemodialyzed patients and kidney transplant recipients. <i>Viruses</i>. 2022;14(10):2224. doi:10.3390/v14102224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/36298779/pubmed" id="36298779" target="_blank">36298779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35643856">
<a name="35643856"></a>Pupo Correia M, Fernandes S, Filipe P. Cutaneous adverse reactions to the new oral antiviral drugs against SARS-CoV-2. <i>Clin Exp Dermatol</i>. 2022;47(9):1738-1740. doi:10.1111/ced.15281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/35643856/pubmed" id="35643856" target="_blank">35643856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36614834">
<a name="36614834"></a>Santi Laurini G, Montanaro N, Motola D. Safety profile of molnupiravir in the teatment of COVID-19: A descriptive study based on FAERS data. <i>J Clin Med</i>. 2022;12(1):34. doi:10.3390/jcm12010034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/36614834/pubmed" id="36614834" target="_blank">36614834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2021">
<a name="FDA.2021"></a>US Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization for molnupiravir. https://www.merck.com/eua/molnupiravir-hcp-fact-sheet.pdf. Published December 23, 2021. Revised February 2023. Accessed February 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization for molnupiravir. https://www.merck.com/eua/molnupiravir-hcp-fact-sheet.pdf. Published December 23, 2021. Revised August 1, 2022. Accessed August 15, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 134694 Version 50.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
